Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
Implements significant cost reduction program
Expects to be sustainably cash flow positive beginning 2H 2022
Investor conference call and webcast today at 8:00 AM ET (5:00 AM PT)
DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 -- (Healthcar... Biopharmaceuticals, Personnel Theravance Biopharma, YUPELRI, revefenacin, COPD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news